Low Dose Naltrexone for Multiple Sclerosis: Symptoms vs. Disease Modification

Low Dose Naltrexone, commonly called LDN, is frequently discussed in multiple sclerosis communities for symptoms such as pain, fatigue, spasticity, mood changes, and reduced quality of life. Those conversations can make it sound as though one question is being asked: Does LDN work for MS?

The better question is more precise: Has LDN been shown to help a particular symptom, or has it been shown to change the underlying course of multiple sclerosis?

Current research does not establish compounded LDN as a disease-modifying treatment for MS. A few small studies have reported improvements in selected quality-of-life measures or spasticity. Other outcomes did not improve, and the available studies have not shown that LDN reduces relapses, prevents new MRI lesions, or slows disability progression.

Direct answer: LDN may be discussed as an off-label, adjunctive option for selected MS symptoms, but it has not been proven to modify the course of multiple sclerosis. It should not replace an FDA-approved MS disease-modifying therapy, or DMT, without direction from the neurologist managing the disease.

Readers who are new to this medication can begin with Scripx Pharmacy’s foundational guide to what Low Dose Naltrexone is, including its uses, evidence, safety, and compounding. For a broader condition-by-condition view, see LDN for autoimmune conditions, including what has actually been studied.

Considering LDN as Part of a Coordinated MS Plan?

If your neurologist or prescribing clinician believes an individualized LDN trial may be appropriate for symptom support, review the Scripx Low Dose Naltrexone prescription page and talk with a Scripx compounding pharmacist about prescription requirements, formulation questions, opioid safety, and medication coordination. Do not stop, reduce, or delay an MS disease-modifying therapy to begin LDN.

All prescription medications require a valid prescription from a licensed healthcare provider. The LDN uses discussed in this article are off label, and compounded medications are not FDA approved.

Why Symptoms and Disease Activity Are Not the Same Thing

Multiple sclerosis can affect movement, sensation, vision, cognition, bladder and bowel function, energy, mood, and pain. A person can feel better in one area while inflammatory disease activity continues. The reverse is also possible: a disease-modifying therapy can reduce relapses or new MRI activity even when an existing symptom remains difficult.

That is why MS care often has two connected, but different, goals.

1. Symptom management aims to improve day-to-day function, comfort, sleep, mobility, mood, or quality of life.

2. Disease modification aims to reduce relapses, new or enlarging MRI lesions, disability accumulation, or other measures of MS activity and progression.

The National Multiple Sclerosis Society’s LDN overview specifically notes that LDN is not considered a disease-modifying therapy. The Society also explains that the FDA has approved more than 20 DMTs for MS, each with defined indications, evidence, and safety monitoring.

This distinction does not make symptom improvement unimportant. It means symptom improvement should not be used as proof that MS inflammation or progression is controlled.

For the broader treatment distinction, read Can LDN replace a biologic or immunosuppressant?.

What Has Actually Been Studied?

The MS evidence for LDN is limited to small pilot trials, short randomized studies, retrospective analyses, and prescription-database research. These designs can identify possible signals, but they do not provide the same level of evidence as larger trials designed to measure relapses, MRI activity, or disability progression.

The 2008 Primary Progressive MS Pilot Study

A six-month, open-label pilot study included 40 people with primary progressive MS. Safety and tolerability were the primary outcomes. Spasticity scores improved, but pain increased, and the study did not find significant changes in fatigue, depression, or quality of life. Because there was no placebo group and the trial was small, it could not establish that LDN changed the course of primary progressive MS. Read the PubMed study summary.

The 2010 University of California Quality-of-Life Trial

A randomized, placebo-controlled crossover trial enrolled 80 people with MS. LDN was associated with improvement in some mental-health quality-of-life measures, pain effects, and self-reported cognitive function. It did not improve several physical quality-of-life measures, including fatigue, bowel and bladder control, sexual satisfaction, and visual function. The trial was short and experienced substantial dropout, limiting the conclusions that can be drawn. Read the PubMed study summary.

The Second 2010 Randomized Trial

Another randomized, placebo-controlled trial evaluated quality of life in people with relapsing-remitting and secondary progressive MS. Its authors reported that efficacy remained uncertain, with no broad, consistent quality-of-life advantage that would establish LDN as an MS treatment. Read the PubMed study summary.

The 2016 Retrospective Study

A retrospective chart review compared a small group receiving LDN alone with another group receiving glatiramer acetate plus LDN. The authors described stable laboratory and clinical measures, but this was not a randomized comparison designed to determine whether LDN prevented relapses or progression. Treatment selection, small groups, incomplete controls, and chart-review methods substantially limit causal conclusions. Read the PubMed study summary.

The 2017 Norwegian Prescription Study

A national prescription-database analysis followed 341 people with MS before and after they began LDN. Starting LDN was not followed by reductions in dispensing of MS disease-modifying medicines or symptom medications. The study measured prescription use, not neurologic outcomes, but it does not support the idea that LDN broadly displaced established MS treatment or symptom management. Read the open-access PLOS ONE study.

The 2026 Evidence Review

A 2026 narrative review evaluated 105 LDN studies across multiple conditions, including 15 randomized controlled trials. Its broader conclusion was that early positive findings were often not replicated in placebo-controlled research and that the overall evidence did not support routine clinical use. For MS specifically, the review reinforces the need to interpret small symptom and quality-of-life signals cautiously. Read the 2026 evidence review.

LDN and MS Evidence at a Glance

 

The most accurate summary is not that LDN “works” or “does not work” for all of MS. It is that small studies have produced mixed symptom and quality-of-life findings, while disease modification remains unproven.

Can LDN Be Used Alongside an MS Disease-Modifying Therapy?

Possibly for selected patients, but the decision is medication specific and should be coordinated with the neurologist, prescriber, and pharmacist.

The absence of a listed interaction does not prove that a combination has been formally studied. The review should include:

1. The exact MS DMT and its monitoring requirements

2. The specific symptom LDN is intended to address

3. The complete prescription, over-the-counter, and supplement list

4. Liver history and relevant laboratory monitoring

5. Current or anticipated opioid use

6. Planned surgery, dental treatment, or emergency pain needs

7. A plan for measuring symptom response without confusing it with MS disease control

Most importantly, LDN should not become a reason to skip DMT doses, delay neurologic follow-up, or reduce MRI and laboratory monitoring.

For a category-by-category medication review, see Can you take LDN with other medications?.

The Opioid Safety Issue Still Applies in MS

LDN uses the same active ingredient as standard naltrexone, an opioid receptor antagonist. The lower dose does not eliminate its ability to interfere with opioid medication.

This matters for people with MS who may need treatment for acute pain, surgery, dental work, injury, or another condition. Naltrexone can block expected opioid analgesia and can precipitate withdrawal in a person who is physiologically dependent on opioids.

Patients should not stop an opioid, create their own opioid-free interval, stop LDN before a procedure, or attempt to overcome the receptor blockade without direct clinical guidance. Everyone involved in a planned procedure or emergency evaluation should know that the patient takes LDN.

Review the full LDN side effects and opioid safety guide and the Scripx guide to LDN drug interactions.

Where Do GLP-1 Medications Fit Into the MS Conversation?

The crossover is real, but it is not evidence that a GLP-1 medicine treats multiple sclerosis.

People living with MS may also have obesity, type 2 diabetes, cardiovascular risk, limited mobility, or other metabolic-health concerns. A GLP-1 receptor agonist or a dual GIP and GLP-1 receptor agonist may be prescribed for an appropriate metabolic indication. That decision should retain its own evidence, goals, contraindications, and monitoring plan.

A 2025 peer-reviewed retrospective study described 49 people with MS who used a GLP-1 medication. Participants had measurable weight loss, and tolerability appeared broadly similar to that reported in the general population. However, four participants developed new demyelinating lesions on MRI and one experienced a new MS attack. The study was small, uncontrolled, and not designed to prove that GLP-1 therapy improved or worsened MS disease activity. Read the study in Neurological Sciences.

The appropriate conclusion is narrow:

1. GLP-1 therapy may be considered for an approved or clinically appropriate metabolic indication in a person who also has MS.

2. Early observational research cannot establish that GLP-1 therapy modifies MS.

3. Weight loss, improved mobility, or better metabolic measures should not be confused with reduced MS inflammatory activity.

4. A GLP-1 medicine should not replace a DMT.

5. There is not adequate evidence to promote LDN plus a GLP-1 as an MS or weight-loss protocol.

If both therapies are being considered, medication coordination matters. GLP-1 therapies can delay gastric emptying and may affect oral medication absorption, gastrointestinal symptoms can overlap, and treatment changes made at the same time can make symptom attribution difficult.

Learn about Scripx Pharmacy’s medically supervised weight-management and GLP-1 services. This link is provided for metabolic-health education and does not establish that LDN and GLP-1 therapy should be combined or that either therapy modifies MS.

How Should an Individual LDN Trial Be Evaluated?

If a neurologist or other qualified prescriber supports an adjunctive LDN trial, the goal should be defined before treatment begins.

“Help my MS” is too broad to measure. A clearer plan might track one or two specific outcomes, such as:

1. Pain severity and interference with daily activities

2. Spasticity frequency or functional impact

3. Sleep quality

4. Fatigue using a consistent rating method

5. Mood or daily function

6. Adverse effects

7. Any change in opioid or procedure needs

Use the same measure at baseline and during follow-up. Avoid starting several medications or supplements simultaneously when the treating team believes a staged approach is appropriate. Most importantly, keep symptom tracking separate from neurologic monitoring of relapses, examination findings, MRI activity, and disability.

Patients comparing compounded preparations can also review 10 questions to ask an LDN compounding pharmacy.

Seven Questions to Ask the Neurologist, Prescriber, and Pharmacist

1. What specific MS symptom are we trying to address with LDN?

2. What evidence supports LDN for that symptom?

3. How will we measure whether it is helping?

4. Will my DMT, MRI schedule, laboratory monitoring, and neurology follow-up remain unchanged?

5. Do any current, recent, or anticipated medications contain an opioid?

6. Could a GLP-1 medicine or another therapy affect absorption, gastrointestinal symptoms, or our ability to identify the cause of a change?

7. When should LDN be continued, adjusted, or stopped by the prescribing clinician?

The Bottom Line

LDN has been studied in multiple sclerosis, but the evidence is small, mixed, and focused mainly on symptoms and quality of life. One trial reported improvement in selected mental-health quality-of-life measures. One open-label study reported reduced spasticity but increased pain. Fatigue and several physical outcomes did not consistently improve.

What has not been shown is even more important for treatment decisions. LDN has not been established to reduce MS relapses, prevent new MRI lesions, or slow disability progression. It is not a proven replacement for an MS disease-modifying therapy.

The GLP-1 crossover should be handled with the same discipline. A GLP-1 medicine may have an appropriate role in obesity, diabetes, or metabolic care for a person with MS, but early observational findings do not make it an MS treatment. There is also insufficient evidence to promote an LDN and GLP-1 combination for MS or enhanced weight loss.

Take the Next Step With Scripx Pharmacy

If your neurologist or licensed prescriber believes LDN may be appropriate as part of a coordinated symptom-management plan, review Scripx Low Dose Naltrexone and begin the prescription process. For formulation, medication-list, opioid-safety, or compounding questions, contact a Scripx compounding pharmacist.

Keep your neurologist involved, continue prescribed MS disease-modifying therapy unless the treating specialist changes it, and make sure every clinician knows about LDN before surgery, dental work, emergency care, or opioid treatment.

All prescriptions require review and approval by a licensed healthcare provider. LDN uses discussed here are off label. Compounded medications are not FDA approved, and individual results vary.

Frequently Asked Questions

Does Low Dose Naltrexone treat multiple sclerosis?

LDN is sometimes prescribed off label for selected symptoms, but it is not FDA approved to treat MS and has not been proven to modify the course of the disease. Small studies have reported mixed findings in quality of life, pain, spasticity, fatigue, and other symptoms.

Can LDN reduce MS relapses?

Current evidence does not establish that LDN reduces annualized relapse rates. The principal LDN studies in MS were not large, long-term trials designed to demonstrate relapse reduction.

Does LDN prevent new MS lesions on MRI?

No reliable clinical evidence has established that LDN prevents new or enlarging MRI lesions. MRI monitoring should continue according to the neurologist’s plan.

Can LDN replace an MS disease-modifying therapy?

No. LDN has not shown the disease-modifying outcomes required to be considered an evidence-based replacement for an MS DMT. Do not stop or delay a DMT without the prescribing neurologist.

Does LDN help MS fatigue?

The available MS trials have not shown a consistent benefit for fatigue. Fatigue can also have multiple contributors, including MS activity, sleep, mood, medication effects, pain, infection, anemia, thyroid disease, and other conditions.

Does LDN help MS spasticity?

A small, open-label study in 40 people with primary progressive MS reported reduced spasticity, but the finding has not been confirmed in a large placebo-controlled trial. It should be treated as an early signal, not established efficacy.

Can LDN be taken with an MS DMT?

Some patients may be prescribed both, but compatibility cannot be generalized across all MS therapies. The neurologist, LDN prescriber, and pharmacist should review the exact DMT, monitoring plan, liver history, opioid exposure, and complete medication list.

Can someone with MS take semaglutide or tirzepatide?

A GLP-1 or dual GIP and GLP-1 medication may be prescribed for an appropriate metabolic indication after individual review. A small retrospective MS cohort reported weight loss and tolerability broadly similar to the general population, but it did not prove benefit for MS disease activity.

Do GLP-1 medications slow MS progression?

That has not been established. Preclinical theories and early observational data are not proof of reduced relapses, MRI activity, or disability progression in people with MS.

Can LDN and a GLP-1 be taken together?

There is no universal rule covering every patient, and direct combination evidence is limited. The care team should review oral medication absorption, gastrointestinal symptoms, the reason for each therapy, the complete medication list, and how treatment response will be measured. LDN should not be promoted as a GLP-1 enhancer or an approved weight-loss treatment.